ORIC Pharmaceuticals, Inc.

Stocks

ORIC

US68622P1093

Market Closed - Nasdaq 16:00:00 2026-09-04 EDT			5-day change	1st Jan Change
12.86 ^USD	+0.94%		-2.87%	+57.21%

08-28	Oric Pharmaceuticals Insider Sold Shares Worth $1,053,814, According to a Recent SEC Filing	MT
08-03	ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Transcript : ORIC Pharmaceuticals, Inc. - Special Call

Published on 03/31/2026 at 10:05 pm EDT - Modified on 04/13/2026 at 07:50 pm EDT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good day, and thank you for standing by. Welcome to the ORIC Pharma Update Conference Call. [Operator Instructions]. Please be advised that today's

This article is reserved for our subscribers.

To unlock the article,
subscribe!

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

Latest news about ORIC Pharmaceuticals, Inc.

08-28	Oric Pharmaceuticals Insider Sold Shares Worth $1,053,814, According to a Recent SEC Filing	MT
08-03	ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-14	ORIC Pharmaceuticals Starts Phase 3 Trial of Rinzimetostat in Metastatic Prostate Cancer	MT
07-14	Oric Pharmaceuticals Initiates Himalayas-1 Global Phase 3 Trial in Patients with Mcrpc Previously Treated with Abiraterone	CI
06-09	ORIC Pharmaceuticals, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 08:00 AM
05-04	ORIC Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-17	ORIC Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings	CI
04-01	Wall Street Set to Open Higher as Trump Says US Will Consider Ceasefire if Hormuz Strait Opened	MT
04-01	Top Premarket Decliners	MT
04-01	Wedbush Cuts Price Target on ORIC Pharmaceuticals to $17 From $20, Keeps Outperform Rating	MT
03-31	ORIC Pharmaceuticals, Inc. - Special Call
03-31	ORIC Pharmaceuticals to Launch Phase 3 Trial of Prostate Cancer Drug Candidate, Shares Falter	MT
03-31	ORIC Pharmaceuticals, Inc. Reports Selection Of Rinzimetostat RP3D In Combination With Darolutamide For Himalayas-1 Phase 3 Global Study With Dose Optimization Data Supporting Its Potential Best-In-Disease Profile	CI
03-27	Oric Pharmaceuticals Reports Combination Dose Optimization Data From Phase 1b Trial Of Rinzimetostat In Patients With Metastatic Castration Resistant Prostate Cancer	CI
03-06	Oric Pharmaceuticals reports inducement grants under Nasdaq listing rule 5635(c)(4)	RE